JP2015511629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511629A5 JP2015511629A5 JP2015502481A JP2015502481A JP2015511629A5 JP 2015511629 A5 JP2015511629 A5 JP 2015511629A5 JP 2015502481 A JP2015502481 A JP 2015502481A JP 2015502481 A JP2015502481 A JP 2015502481A JP 2015511629 A5 JP2015511629 A5 JP 2015511629A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pyridin
- ylmethyl
- triazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 nitro, hydroxy Chemical group 0.000 claims 79
- 150000001875 compounds Chemical class 0.000 claims 35
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 13
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 150000001204 N-oxides Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- DEBZZZPGFBEZBW-UHFFFAOYSA-N N-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NC1=CC=C2C(=N1)N(N=N2)CC=1C=C2C=CC=NC2=CC=1 DEBZZZPGFBEZBW-UHFFFAOYSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- WDAXFOBOLVPGLV-UHFFFAOYSA-N isobutyric acid ethyl ester Natural products CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 229950010765 pivalate Drugs 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- QNUASQXVZJWQBW-UHFFFAOYSA-N 1-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]ethanone Chemical compound N1=CC=CC2=CC(CN3C=NC4=CC=C(N=C43)C(=O)C)=CC=C21 QNUASQXVZJWQBW-UHFFFAOYSA-N 0.000 claims 1
- AXGSZRSRDMYBMK-UHFFFAOYSA-N 1-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]-n-methoxyethanimine;hydrochloride Chemical compound Cl.C1=CN=C2C=C(F)C(CN3N=NC4=CC=C(N=C43)C(C)=NOC)=CC2=C1 AXGSZRSRDMYBMK-UHFFFAOYSA-N 0.000 claims 1
- QYPDLRROIKAURY-UHFFFAOYSA-N 1-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]ethanone Chemical compound C1=CN=C2C=C(F)C(CN3N=NC4=CC=C(N=C43)C(=O)C)=CC2=C1 QYPDLRROIKAURY-UHFFFAOYSA-N 0.000 claims 1
- LXHNRPXNNMAFTI-UHFFFAOYSA-N 2,6-difluoro-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=C(F)C(C(=O)O)=C(F)C=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 LXHNRPXNNMAFTI-UHFFFAOYSA-N 0.000 claims 1
- PIKJMYAHJUMBAC-UHFFFAOYSA-N 2,6-difluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(F)C(C(=O)N)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 PIKJMYAHJUMBAC-UHFFFAOYSA-N 0.000 claims 1
- JCISGNLLEVOIIT-UHFFFAOYSA-N 2-[1-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]ethylideneamino]oxyethylurea Chemical compound N1=CC=CC2=CC(CN3N=NC4=CC=C(N=C43)C(=NOCCNC(N)=O)C)=CC=C21 JCISGNLLEVOIIT-UHFFFAOYSA-N 0.000 claims 1
- GJQFPKFKHPOFJB-UHFFFAOYSA-N 2-[1-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]ethylideneamino]oxyethanol Chemical compound C1=CN=C2C=C(F)C(CN3N=NC4=CC=C(N=C43)C(=NOCCO)C)=CC2=C1 GJQFPKFKHPOFJB-UHFFFAOYSA-N 0.000 claims 1
- ZVLAVSMGJAYDHL-UHFFFAOYSA-N 2-[1-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]ethylideneamino]oxyethanol;hydrochloride Chemical compound Cl.C1=CN=C2C=C(F)C(CN3N=NC4=CC=C(N=C43)C(=NOCCO)C)=CC2=C1 ZVLAVSMGJAYDHL-UHFFFAOYSA-N 0.000 claims 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 claims 1
- JBLIPQDYRNUBON-UHFFFAOYSA-N 2-chloro-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 JBLIPQDYRNUBON-UHFFFAOYSA-N 0.000 claims 1
- REQQUNOUUNUVSW-UHFFFAOYSA-N 2-chloro-4-[3-[(7-fluoro-1-oxidoquinolin-1-ium-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)N)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=[N+]([O-])C=CC=C4C=3)F)C2=N1 REQQUNOUUNUVSW-UHFFFAOYSA-N 0.000 claims 1
- IEIJPGCZDVVTGF-UHFFFAOYSA-N 2-chloro-n-(2-hydroxy-2-methylpropoxy)-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)NOCC(C)(O)C)=CC=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 IEIJPGCZDVVTGF-UHFFFAOYSA-N 0.000 claims 1
- BRSYEFMPOGCMCI-UHFFFAOYSA-N 2-chloro-n-(2-hydroxyethoxy)-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)NOCCO)=CC=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 BRSYEFMPOGCMCI-UHFFFAOYSA-N 0.000 claims 1
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 1
- LZYCSJFSOVZBKW-UHFFFAOYSA-N 4-[3-(1,3-benzothiazol-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]-2,6-difluorobenzamide Chemical compound C1=C(F)C(C(=O)N)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4SC=NC4=CC=3)C2=N1 LZYCSJFSOVZBKW-UHFFFAOYSA-N 0.000 claims 1
- HMHGGOLCAGMLOF-UHFFFAOYSA-N 4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]-2-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(C(=O)N)=CC=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 HMHGGOLCAGMLOF-UHFFFAOYSA-N 0.000 claims 1
- NAQNOOPPCTUYMT-UHFFFAOYSA-N 4-[3-[(5,7-difluoroquinolin-6-yl)methyl]imidazo[4,5-b]pyridin-5-yl]-2-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(C(=O)N)=CC=C1C1=CC=C(N=CN2CC=3C(=C4C=CC=NC4=CC=3F)F)C2=N1 NAQNOOPPCTUYMT-UHFFFAOYSA-N 0.000 claims 1
- TVGRZVKKRUTZCU-UHFFFAOYSA-N 4-[3-[(5,7-difluoroquinolin-6-yl)methyl]imidazo[4,5-b]pyridin-5-yl]-2-methylbenzamide Chemical compound C1=C(C(N)=O)C(C)=CC(C=2N=C3N(CC=4C(=C5C=CC=NC5=CC=4F)F)C=NC3=CC=2)=C1 TVGRZVKKRUTZCU-UHFFFAOYSA-N 0.000 claims 1
- GVTGBYYHUJVDCQ-UHFFFAOYSA-N 4-[3-[(7-fluoroquinolin-6-yl)methyl]imidazo[4,5-b]pyridin-5-yl]-2-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(C(=O)N)=CC=C1C1=CC=C(N=CN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 GVTGBYYHUJVDCQ-UHFFFAOYSA-N 0.000 claims 1
- QJCRAKNGMUECSE-UHFFFAOYSA-N 4-[3-[(7-fluoroquinolin-6-yl)methyl]imidazo[4,5-b]pyridin-5-yl]-2-methylbenzamide Chemical compound C1=C(C(N)=O)C(C)=CC(C=2N=C3N(CC=4C(=CC5=NC=CC=C5C=4)F)C=NC3=CC=2)=C1 QJCRAKNGMUECSE-UHFFFAOYSA-N 0.000 claims 1
- JMIUGOGTLNHALB-UHFFFAOYSA-N 4-[3-[(7-fluoroquinolin-6-yl)methyl]imidazo[4,5-b]pyridin-5-yl]-2-methylbenzamide;hydrochloride Chemical compound Cl.C1=C(C(N)=O)C(C)=CC(C=2N=C3N(CC=4C(=CC5=NC=CC=C5C=4)F)C=NC3=CC=2)=C1 JMIUGOGTLNHALB-UHFFFAOYSA-N 0.000 claims 1
- ZDERFVZBKMRCQG-UHFFFAOYSA-N 4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]-n-(2-hydroxyethoxy)-2-methylbenzamide Chemical compound C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C(=CC5=NC=CC=C5C=4)F)N=NC3=CC=2)=C1 ZDERFVZBKMRCQG-UHFFFAOYSA-N 0.000 claims 1
- FYSMQMYUXKAKKJ-UHFFFAOYSA-N 4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]-n-(2-hydroxyethoxy)-2-methylbenzamide;hydrochloride Chemical compound Cl.C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C(=CC5=NC=CC=C5C=4)F)N=NC3=CC=2)=C1 FYSMQMYUXKAKKJ-UHFFFAOYSA-N 0.000 claims 1
- GHFMBHGMYUMPCY-UHFFFAOYSA-N 5-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound N1=CC=CC2=CC(CN3C=NC4=CC=C(N=C43)C=3C=C4CNC(C4=CC=3)=O)=CC=C21 GHFMBHGMYUMPCY-UHFFFAOYSA-N 0.000 claims 1
- WTMZIJSENRMDDW-UHFFFAOYSA-N 5-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound N1=CC=CC2=CC(CN3N=NC4=CC=C(N=C43)C=3C=C4CNC(C4=CC=3)=O)=CC=C21 WTMZIJSENRMDDW-UHFFFAOYSA-N 0.000 claims 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- XYKMCOLDHRKURL-UHFFFAOYSA-N C(C)C1=C(OC=C1)C(=O)ONCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)C Chemical class C(C)C1=C(OC=C1)C(=O)ONCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)C XYKMCOLDHRKURL-UHFFFAOYSA-N 0.000 claims 1
- YXDKAAQMVCOEOL-UHFFFAOYSA-N CC(=NO)c1ccc2nnn(Cc3cc4cccnc4cc3F)c2n1 Chemical compound CC(=NO)c1ccc2nnn(Cc3cc4cccnc4cc3F)c2n1 YXDKAAQMVCOEOL-UHFFFAOYSA-N 0.000 claims 1
- FAGBNADIPVHBRY-UHFFFAOYSA-N CC(=NOCCN)c1ccc2nnn(Cc3ccc4ncccc4c3)c2n1 Chemical compound CC(=NOCCN)c1ccc2nnn(Cc3ccc4ncccc4c3)c2n1 FAGBNADIPVHBRY-UHFFFAOYSA-N 0.000 claims 1
- AJBJSTRLWOVZTN-UHFFFAOYSA-N CC(=NOCCO)c1ccc2nnn(Cc3ccc4ncccc4c3)c2n1 Chemical compound CC(=NOCCO)c1ccc2nnn(Cc3ccc4ncccc4c3)c2n1 AJBJSTRLWOVZTN-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018852 Haematoma Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- VRIWGOIUDMSOLM-UHFFFAOYSA-N N-[1-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]ethylidene]hydroxylamine hydrochloride Chemical compound Cl.CC(=NO)c1ccc2nnn(Cc3cc4cccnc4cc3F)c2n1 VRIWGOIUDMSOLM-UHFFFAOYSA-N 0.000 claims 1
- HVBCPZGKXVKFNC-UHFFFAOYSA-N N-hydroxy-2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound Cc1cc(ccc1C(=O)NO)-c1ccc2nnn(Cc3ccc4ncccc4c3)c2n1 HVBCPZGKXVKFNC-UHFFFAOYSA-N 0.000 claims 1
- ZXOWVMPQHDOBOU-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)CN1C=NC=2C1=NC(=CC2)C(C)=NNC(=O)N Chemical compound N1=CC=CC2=CC(=CC=C12)CN1C=NC=2C1=NC(=CC2)C(C)=NNC(=O)N ZXOWVMPQHDOBOU-UHFFFAOYSA-N 0.000 claims 1
- XIIGIIPVKKHOCP-UHFFFAOYSA-N NC(=O)c1c(F)cc(cc1F)-c1ccc2nnn(Cc3ccc4[n+]([O-])cccc4c3)c2n1 Chemical compound NC(=O)c1c(F)cc(cc1F)-c1ccc2nnn(Cc3ccc4[n+]([O-])cccc4c3)c2n1 XIIGIIPVKKHOCP-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- KMBSLDHUDPDCBQ-UHFFFAOYSA-N [1-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]ethylideneamino]urea Chemical compound N1=CC=CC2=CC(CN3N=NC4=CC=C(N=C43)C(=NNC(N)=O)C)=CC=C21 KMBSLDHUDPDCBQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- LEHOGBUBQSGCOK-UHFFFAOYSA-N aminothiourea;hydron;chloride Chemical compound Cl.NNC(N)=S LEHOGBUBQSGCOK-UHFFFAOYSA-N 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- HJWZGBLHCOJSHP-UHFFFAOYSA-N methyl 2,6-difluoro-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=C(F)C(C(=O)OC)=C(F)C=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 HJWZGBLHCOJSHP-UHFFFAOYSA-N 0.000 claims 1
- VNVFJQQRZLDHQC-UHFFFAOYSA-N n,2-dimethyl-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(C)C(C(=O)NC)=CC=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 VNVFJQQRZLDHQC-UHFFFAOYSA-N 0.000 claims 1
- LJLVUFBLBCLUNL-UHFFFAOYSA-N n-(2-hydroxy-2-methylpropoxy)-2-methyl-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(C(=O)NOCC(C)(C)O)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)C=NC3=CC=2)=C1 LJLVUFBLBCLUNL-UHFFFAOYSA-N 0.000 claims 1
- CBWJNRHRHLOAJE-UHFFFAOYSA-N n-(2-hydroxyethoxy)-2-methyl-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)C=NC3=CC=2)=C1 CBWJNRHRHLOAJE-UHFFFAOYSA-N 0.000 claims 1
- YVRBWLQYYXUGNX-UHFFFAOYSA-N n-(2-hydroxyethoxy)-2-methyl-4-[3-[(1-oxidoquinolin-1-ium-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzamide Chemical class C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=[N+]([O-])C5=CC=4)N=NC3=CC=2)=C1 YVRBWLQYYXUGNX-UHFFFAOYSA-N 0.000 claims 1
- XKRYOBGPPUUVDK-UHFFFAOYSA-N n-[1-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]ethylideneamino]pyridin-2-amine Chemical compound C=1C=C2N=NN(CC=3C=C4C=CC=NC4=CC=3)C2=NC=1C(C)=NNC1=CC=CC=N1 XKRYOBGPPUUVDK-UHFFFAOYSA-N 0.000 claims 1
- WDUNIZICWLRJPP-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(=O)NCCCN(C)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 WDUNIZICWLRJPP-UHFFFAOYSA-N 0.000 claims 1
- KAAHHLOYOIUHHH-UHFFFAOYSA-N n-methoxyethanimine Chemical compound CON=CC KAAHHLOYOIUHHH-UHFFFAOYSA-N 0.000 claims 1
- DWDBEYGCEVFWPN-UHFFFAOYSA-N n-methyl-5-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 DWDBEYGCEVFWPN-UHFFFAOYSA-N 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- KSROGBCLOUKHHL-UHFFFAOYSA-M sodium [2,6-difluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoyl]-(2-hydroxyethoxy)azanide Chemical compound [Na+].OCCO[N-]C(=O)c1c(F)cc(cc1F)-c1ccc2nnn(Cc3ccc4ncccc4c3)c2n1 KSROGBCLOUKHHL-UHFFFAOYSA-M 0.000 claims 1
- QEZKMMVSLTZOJP-UHFFFAOYSA-M sodium [2,6-difluoro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoyl]-(2-hydroxyethoxy)azanide Chemical compound [Na+].OCCO[N-]C(=O)c1c(F)cc(cc1F)-c1ccc2nnn(Cc3cc4cccnc4cc3F)c2n1 QEZKMMVSLTZOJP-UHFFFAOYSA-M 0.000 claims 1
- QQWVSVSAOUICGI-UHFFFAOYSA-M sodium [2-chloro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoyl]-(2-hydroxyethoxy)azanide Chemical compound [Na+].OCCO[N-]C(=O)c1ccc(cc1Cl)-c1ccc2nnn(Cc3ccc4ncccc4c3)c2n1 QQWVSVSAOUICGI-UHFFFAOYSA-M 0.000 claims 1
- QSVSMLSZVBDQPS-UHFFFAOYSA-M sodium [2-chloro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoyl]-(2-hydroxyethoxy)azanide Chemical compound [Na+].OCCO[N-]C(=O)c1ccc(cc1Cl)-c1ccc2nnn(Cc3cc4cccnc4cc3F)c2n1 QSVSMLSZVBDQPS-UHFFFAOYSA-M 0.000 claims 1
- WCZQGNLQIYMETI-UHFFFAOYSA-M sodium [4-[3-(1,3-benzothiazol-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]-2,6-difluorobenzoyl]-(2-hydroxyethoxy)azanide Chemical compound [Na+].OCCO[N-]C(=O)c1c(F)cc(cc1F)-c1ccc2nnn(Cc3ccc4ncsc4c3)c2n1 WCZQGNLQIYMETI-UHFFFAOYSA-M 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1262CH2012 | 2012-03-30 | ||
| IN1262/CHE/2012 | 2012-03-30 | ||
| PCT/IB2013/051577 WO2013144737A2 (en) | 2012-03-30 | 2013-02-27 | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511629A JP2015511629A (ja) | 2015-04-20 |
| JP2015511629A5 true JP2015511629A5 (enExample) | 2016-04-14 |
| JP6192708B2 JP6192708B2 (ja) | 2017-09-06 |
Family
ID=48093046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015502481A Expired - Fee Related JP6192708B2 (ja) | 2012-03-30 | 2013-02-27 | Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9815831B2 (enExample) |
| EP (1) | EP2831073B1 (enExample) |
| JP (1) | JP6192708B2 (enExample) |
| KR (2) | KR20140144726A (enExample) |
| CN (2) | CN107082779A (enExample) |
| AP (1) | AP3908A (enExample) |
| AU (1) | AU2013239398B2 (enExample) |
| BR (1) | BR112014024251A8 (enExample) |
| CA (1) | CA2865719C (enExample) |
| CL (1) | CL2014002604A1 (enExample) |
| CO (1) | CO7111276A2 (enExample) |
| EA (1) | EA026412B1 (enExample) |
| ES (1) | ES2856848T3 (enExample) |
| IL (1) | IL234513B (enExample) |
| MX (1) | MX359888B (enExample) |
| MY (1) | MY169268A (enExample) |
| NZ (1) | NZ629499A (enExample) |
| PH (1) | PH12014502166B1 (enExample) |
| SG (1) | SG11201406185WA (enExample) |
| WO (1) | WO2013144737A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2715611T3 (es) * | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
| CN107082779A (zh) * | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
| GB201321741D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| SG10201912699RA (en) * | 2015-07-20 | 2020-02-27 | Genzyme Corp | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
| CN107573340B (zh) * | 2017-10-23 | 2020-11-24 | 江西科技师范大学 | 2-氨甲酰基-4-芳杂吡啶类化合物的制备及应用 |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| MX2023012726A (es) * | 2021-04-29 | 2024-01-04 | Amgen Inc | Compuestos heterociclicos y metodos de uso. |
| CN114031562A (zh) * | 2021-10-31 | 2022-02-11 | 南京碳硅人工智能生物医药技术研究院有限公司 | 一种具有抗肿瘤的吡啶衍生物的工艺优化 |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE69312700T2 (de) | 1992-04-14 | 1998-02-19 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
| US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| AU5131998A (en) | 1997-01-06 | 1998-08-03 | Pfizer Inc. | Cyclic sulfone derivatives |
| ES2202796T3 (es) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | Derivados de acidos arilsulfonilaminohidroxamicos. |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| SK287200B6 (sk) | 1999-02-22 | 2010-03-08 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie |
| CA2534027A1 (en) | 2003-06-19 | 2005-01-27 | Dennis Drayna | Variants of human taste receptor genes |
| CA2536470A1 (en) | 2003-08-15 | 2005-02-24 | Vertex Pharmaceuticals Incorporated | Pyrrole compositions useful as inhibitors of c-met |
| AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| EP1697352B1 (en) | 2003-09-24 | 2012-06-27 | Vertex Pharmceuticals Incorporated | 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| WO2006021886A1 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| BRPI0513915A (pt) | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
| NZ552946A (en) | 2004-08-26 | 2010-09-30 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| EP1812440B1 (en) | 2004-11-04 | 2010-09-22 | Vertex Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| CA2603748A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
| US7470693B2 (en) | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2007064797A2 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| RU2008141761A (ru) | 2006-03-22 | 2010-04-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| NZ575548A (en) | 2006-09-18 | 2011-09-30 | Vertex Pharma | Heterocyclic inhibitors of c-Met and uses thereof |
| NZ576278A (en) * | 2006-10-19 | 2011-12-22 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| PL2081937T3 (pl) | 2006-10-23 | 2013-01-31 | Sgx Pharmaceuticals Inc | Triazolopirydazynowe modulatory kinaz białkowych |
| EP2078003B1 (en) | 2006-10-31 | 2017-03-08 | Merck Sharp & Dohme Corp. | Anilinopiperazine derivatives and methods of use thereof |
| WO2008060866A1 (en) | 2006-11-14 | 2008-05-22 | Smithkline Beecham Corporation | Novel compounds |
| WO2008078085A1 (en) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Method |
| CA2675755C (en) | 2007-01-19 | 2015-10-06 | Xcovery, Inc. | Pyridine and pyridazine derivatives as kinase inhibitors |
| KR20090090365A (ko) | 2007-02-23 | 2009-08-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Ｈｇｆｒ 유전자 증폭 세포주에 대하여 우수한 세포 증식 억제 효과 및 항종양 효과를 나타내는 피리딘 유도체 또는 피리미딘 유도체 |
| FR2915198B1 (fr) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| US8304425B2 (en) | 2007-06-22 | 2012-11-06 | Arqule, Inc. | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer |
| EP2217595A1 (en) | 2007-10-29 | 2010-08-18 | Schering Corporation | Diamido thiazole derivatives as protein kinase inhibitors |
| WO2009058728A1 (en) | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
| CN101910167A (zh) | 2007-10-29 | 2010-12-08 | 先灵公司 | 噻唑甲酰胺衍生物及其治疗癌症 |
| MX2010004880A (es) | 2007-10-29 | 2010-07-28 | Schering Corp | Derivados heterociclicos de urea y tiourea, y metodos de uso de los mismos. |
| CA2722220C (en) * | 2008-04-30 | 2016-06-07 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
| HUE025504T2 (en) * | 2009-12-31 | 2016-02-29 | Hutchison Medipharma Ltd | Certain triazolopyrazines, compositions thereof and methods of use therefor |
| CN102127096A (zh) | 2009-12-31 | 2011-07-20 | 和记黄埔医药（上海）有限公司 | 三氮唑并吡啶和三氮唑并吡嗪化合物及其组合物和应用 |
| ES2715611T3 (es) * | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
| CN107082779A (zh) * | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
| US9887269B2 (en) * | 2015-11-30 | 2018-02-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-gate device and method of fabrication thereof |
-
2013
- 2013-02-27 CN CN201710062943.0A patent/CN107082779A/zh active Pending
- 2013-02-27 ES ES13716061T patent/ES2856848T3/es active Active
- 2013-02-27 EA EA201491520A patent/EA026412B1/ru unknown
- 2013-02-27 KR KR1020147030532A patent/KR20140144726A/ko not_active Ceased
- 2013-02-27 AU AU2013239398A patent/AU2013239398B2/en not_active Ceased
- 2013-02-27 WO PCT/IB2013/051577 patent/WO2013144737A2/en not_active Ceased
- 2013-02-27 EP EP13716061.0A patent/EP2831073B1/en not_active Not-in-force
- 2013-02-27 AP AP2014007966A patent/AP3908A/en active
- 2013-02-27 KR KR1020207002779A patent/KR102164317B1/ko not_active Expired - Fee Related
- 2013-02-27 SG SG11201406185WA patent/SG11201406185WA/en unknown
- 2013-02-27 NZ NZ629499A patent/NZ629499A/en not_active IP Right Cessation
- 2013-02-27 BR BR112014024251A patent/BR112014024251A8/pt not_active IP Right Cessation
- 2013-02-27 CN CN201380022471.6A patent/CN104321322A/zh active Pending
- 2013-02-27 US US14/389,336 patent/US9815831B2/en not_active Expired - Fee Related
- 2013-02-27 JP JP2015502481A patent/JP6192708B2/ja not_active Expired - Fee Related
- 2013-02-27 MY MYPI2014002712A patent/MY169268A/en unknown
- 2013-02-27 MX MX2014011750A patent/MX359888B/es active IP Right Grant
- 2013-02-27 CA CA2865719A patent/CA2865719C/en active Active
-
2014
- 2014-09-07 IL IL234513A patent/IL234513B/en active IP Right Grant
- 2014-09-26 PH PH12014502166A patent/PH12014502166B1/en unknown
- 2014-09-29 CL CL2014002604A patent/CL2014002604A1/es unknown
- 2014-10-28 CO CO14238774A patent/CO7111276A2/es unknown
-
2017
- 2017-09-14 US US15/705,005 patent/US11066402B2/en not_active Expired - Fee Related
-
2021
- 2021-05-30 US US17/303,494 patent/US20210371416A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511629A5 (enExample) | ||
| CA2395717C (en) | Fused imidazolium derivatives | |
| JP7602272B2 (ja) | Ｋｒａｓ関連がんを治療する方法 | |
| JP2013536193A5 (enExample) | ||
| JP2022185107A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2016506387A5 (enExample) | ||
| JP2020503297A5 (enExample) | ||
| JP2010508288A5 (enExample) | ||
| JP2017525757A5 (enExample) | ||
| JP2016503786A5 (enExample) | ||
| JP2009544600A5 (enExample) | ||
| JP2016523923A5 (enExample) | ||
| CA3081983A1 (en) | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | |
| JP2010539110A5 (enExample) | ||
| JP2020503299A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2016531113A5 (enExample) | ||
| JP2016520131A5 (enExample) | ||
| JP2005501120A5 (enExample) | ||
| CA2412968A1 (en) | Substituted pyridines as selective cyclooxygenase-2 inhibitors | |
| JP2005517006A5 (enExample) | ||
| JP2018529690A5 (enExample) | ||
| JP2014518853A5 (enExample) | ||
| JP2017519754A5 (enExample) |